Q1 2025 C Rad AB Earnings Call Transcript
Key Points
- C-Rad AB (FRA:24C) reported a solid order intake of SEK97 million, marking a 5% growth compared to Q1 last year.
- The company achieved a revenue increase of 1% to SEK119 million, driven by strong deliveries in America and APAC.
- Order intake for services grew by 58% compared to Q1 last year, highlighting the company's focus on growing recurring revenue.
- C-Rad AB (FRA:24C) maintained a solid underlying EBIT margin of 18%, excluding unrealized currency effects, due to cost efficiency measures.
- The company has a strong balance sheet with no long-term debt, and cash balances increased by SEK10 million during the quarter.
- Order intake for the Americas decreased by 21% to SEK19 million in Q1, affected by market uncertainty and tariffs.
- Revenue in EMEA was down 39% to SEK36 million, impacted by lower order intake from the previous year.
- The EBIT for the first quarter was SEK10 million, down from SEK14.2 million a year ago, affected by unrealized exchange rate losses.
- The overall US market is experiencing slowness in decision-making due to tariff-related uncertainties.
- Despite the revenue growth, the gross margin was slightly offset by sales of lower-margin products.
Welcome to our Q1 presentation.
We started the year with a solid quarter in a wait and see market. As most of C Rad is active within radiation therapy, and more than 50% of all cancer patients undergo radiation therapy at some point of the treatment.
And our focus at C Rad is the M2M surface guided workflow from CT room to treatment room, where our surface guided radiation technology or SGRT supports that the dose reaches the tumor and not the healthy tissue of the patient.
But Let me first zoom out and remind you of C Rad 's long-term strategy and priorities. Also, as many of we have announced our medium-term financial targets, which I will come back to later on in the presentation.
So first, I will take you through our progress for Q1.
Let me take you through the slide, left to right. So first, I will start to the left with the market. We see C Rad have a global reach and expanding step by step to grow our sales.
And in line with our ambition to grow in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
